Abyssomicins—A 20-Year Retrospective View

Abyssomicins represent a new family of polycyclic macrolactones. The first described compounds of the abyssomicin family were abyssomicin B, C, atrop-C, and D, produced by the marine actinomycete strain Verrucosispora maris AB-18-032, which was isolated from a sediment collected in the Sea of Japan. Among the described abyssomicins, only abyssomicin C and atrop-abyssomicin C show a high antibiotic activity against Gram-positive bacteria, including multi-resistant and vancomycin-resistant strains. The inhibitory activity is caused by a selective inhibition of the enzyme 4-amino-4-deoxychorismate synthase, which catalyzes the transformation of chorismate to para-aminobenzoic acid, an intermediate in the folic acid pathway.


Introduction
An efficient search for new bioactive compounds, such as antibiotics, demands specific requirements: First, there is a need for a massive set of taxonomically characterized and dereplicated microorganisms isolated from terrestrial and/or marine habitats, with a high potency of producing unique secondary metabolites. A representative example of such a source are members of the order Actinomycetales, which are known as potent producers of unique secondary metabolites. Second, there needs to be a specific target that is essential for a pathogenic organism but is not present in humans in order to provide selectivity in toxic effects. Third, highly efficient analytic equipment and techniques are required to identify novel secondary metabolites in the culture broth or extracts from mycelium and culture filtrate, such as the combination of HPLC with diode array detection and/or mass spectrometry and characterization employing a home-made or commercial database. One of our screening programs was focused on the inhibition of the chorismate pathway, taking over an idea of Emeritus Professor Hans Zähner, one of the pioneers in antibiotic research and chair of the Institute of Microbiology for over 30 years at the University of Tübingen, who retired in 1994. The chorismate pathway leads to the biosynthesis of the aromatic amino acids, and to the biosynthesis of para-aminobenzoic acid (pAba), an intermediate in the biosynthesis of folic acid. This pathway is present in plants, fungi, prokaryotes, and some parasites, such as Plasmodium and Toxoplasma, but it is not present in humans ( Figure 1). The biosynthesis of pAba is catalyzed by two enzymes, 4-amino-4-deoxychorismic acid (ADC) synthase and ADC lyase, which were the target of our screening concept.
As promising candidates for the production of new secondary metabolites, we selected 201 characterized strains from our own collection and strains from my collaborators Alan T. Bull (University of Kent) and Michael Goodfellow (Newcastle University) belonging to the families Streptomycetaceae and Micromonosporaceae, and rare actinomycete genera, isolated both from terrestrial and marine habitats. Extracts were subjected to the screening assay based on a simple but highly selective agar plate diffusion assay. Only one extract obtained from strain AB-18-032, a marine isolate from a sediment collected from the Sea of As promising candidates for the production of new secondary metabolites, we selected 201 characterized strains from our own collection and strains from my collaborators Alan T. Bull (University of Kent) and Michael Goodfellow (Newcastle University) belonging to the families Streptomycetaceae and Micromonosporaceae, and rare actinomycete genera, isolated both from terrestrial and marine habitats. Extracts were subjected to the screening assay based on a simple but highly selective agar plate diffusion assay. Only one extract obtained from strain AB-18-032, a marine isolate from a sediment collected from the Sea of Japan belonging to the family Micromonosporaceae, inhibited pAba biosynthesis selectively. The secondary metabolite pattern of the active extract was analyzed by HPLC-diode array, whereby three metabolites were characterized by our HPLC-UV-Vis Database as presumably new compounds, which we named abyssomicins.
The first announcement of abyssomicins was done two years later in 2003 in a patent application [1] because of their pharmacologically relevant properties which favored their application as promising therapeutics against infection diseases, especially of pathogenic multi-resistant Gram-positive bacteria, including vancomycin-resistant Staphylococcus aureus. Subsequently, we published the screening method, fermentation, isolation, and biological activities of abyssomicins and the taxonomy of the producing strain [2]. Structure elucidation of abyssomicins and their mode of action was done by the group of Roderich Süssmuth (Technical University Berlin) [3][4][5]. The complete characterization of strain AB-18-032 applying polyphasic taxonomy was done by the group of Michael Goodfellow (Newcastle University). Strain AB-18-032 was classified in the genus Verrucosispora as a new species and was named Verrucosispora maris sp. nov. as a type strain [6]. Investigations The first announcement of abyssomicins was done two years later in 2003 in a patent application [1] because of their pharmacologically relevant properties which favored their application as promising therapeutics against infection diseases, especially of pathogenic multi-resistant Gram-positive bacteria, including vancomycin-resistant Staphylococcus aureus. Subsequently, we published the screening method, fermentation, isolation, and biological activities of abyssomicins and the taxonomy of the producing strain [2]. Structure elucidation of abyssomicins and their mode of action was done by the group of Roderich Süssmuth (Technical University Berlin) [3][4][5]. The complete characterization of strain AB-18-032 applying polyphasic taxonomy was done by the group of Michael Goodfellow (Newcastle University). Strain AB-18-032 was classified in the genus Verrucosispora as a new species and was named Verrucosispora maris sp. nov. as a type strain [6]. Investigations in the genetic analysis and description of the whole genome sequence of Verrucosispora maris AB-18-023 were done by the groups of Roderich Süssmuth and James E.M Stach (Newcastle University) [7,8]. The structures of the main compounds produced by Verrucosispora maris AB-18-023, abyssomicin C and atrop-abyssomicin C, are shown in Figure 2.
During the last years, numerous members of the abyssomicin family were isolated from actinomycetes from marine and terrestrial habitats, which was summarized in two excellent review articles [9,10]. Compared with all other described members of the abyssomicin family, only abyssomicin C and atrop-abyssomicin C, the main products of Verrucosispora maris AB18-032, showed potent inhibitory activity against Gram-positive bacteria, caused by the specific inhibition of the p-aminobenzoic acid/tetrahydrofolate biosynthetic pathway. During the last years, numerous members of the abyssomicin from actinomycetes from marine and terrestrial habitats, which was excellent review articles [9,10]. Compared with all other described m somicin family, only abyssomicin C and atrop-abyssomicin C, the m rucosispora maris AB18-032, showed potent inhibitory activity agains teria, caused by the specific inhibition of the p-aminobenzoic acid/ synthetic pathway.

The Screening Concept
As described above, we have been choosing the chorismate pa the pAba biosynthesis as the target for our search of new inhibitors, no specific natural inhibitor of pAba biosynthesis was known that re of the folic acid biosynthesis, which is essential for microorganisms [2].
In a pre-screen, we tested extracts of actinomycetes in a filter dis assay with Bacillus subtilis as the test organism. The only extracts o showing an inhibition zone grown on a chemically defined mediu zone grown on a complex medium. That indicates an antagonistic ef stituent of the complex medium. These extracts were selected for a that enabled us to distinguish between an inhibition of the aromatic a Tyr/Phe/Trp and the pathway of pAba, and simultaneously the inhib prior to chorismate. Four agar plates were prepared seeded with B. su defined medium. A filter paper strip was soaked with an extract an plate. Across the antibiotic containing strip, a second strip was pla

The Screening Concept
As described above, we have been choosing the chorismate pathway and its link to the pAba biosynthesis as the target for our search of new inhibitors, because at this time, no specific natural inhibitor of pAba biosynthesis was known that results in an inhibition of the folic acid biosynthesis, which is essential for microorganisms but not for humans [2].
In a pre-screen, we tested extracts of actinomycetes in a filter disk agar plate diffusion assay with Bacillus subtilis as the test organism. The only extracts of interest were those showing an inhibition zone grown on a chemically defined medium, and no inhibition zone grown on a complex medium. That indicates an antagonistic effect caused by a constituent of the complex medium. These extracts were selected for an antagonism assay that enabled us to distinguish between an inhibition of the aromatic amino acids pathway Tyr/Phe/Trp and the pathway of pAba, and simultaneously the inhibition of the pathway prior to chorismate. Four agar plates were prepared seeded with B. subtilis in a chemically defined medium. A filter paper strip was soaked with an extract and placed on the agar plate. Across the antibiotic containing strip, a second strip was placed that was soaked with a solution of (a) Tyr+Trp+Phe+pAba, (b) Tyr+Phe, (c) Trp, or (d) pAba. When the growth inhibition is competitively reversed exclusively by (a), an inhibitor of an enzyme in front of chorismate can be assumed. An inhibitor of the biosynthetic pathway from chorismate to pAba can be expected when the growth inhibition caused by an extract is competitively reversed by (d). The observance of inhibition zones for (b) and (c) indicates the detection of inhibitors of the aromatic amino acid pathways, Tyr/Phe and Trp, respectively.
This screening program included 201 actinomycetes strains from our own strain collection and strains that we obtained from our collaborators Alan Bull (University of Kent) and Michael Goodfellow (Newcastle University). These were in detail 104 terrestrial members of the family Streptomycetaceae, 33 members of the family Micromonosporaceae (8 terrestrial, 25 marine), and 64 members of rare actinomycete taxa (55 terrestrial, 9 marine). The actinomycetes strains were cultivated in various media, and extracts of their culture filtrates and mycelia were prepared, resulting in 930 extracts that were applied to the assay.
Among all extracts, only one extract from marine strain AB-18-032 inhibited selectively the pathway from chorismate to pAba, indicating an inhibitor of the pAba biosynthesis. The secondary metabolite profile of the active extract determined by HPLC-diode array analysis showed three peaks that could not be assigned to any known antibiotic by means of our HPLC-UV-Vis Database (Figure 3). tively the pathway from chorismate to pAba, indicating an inhibi thesis. The secondary metabolite profile of the active extract deter array analysis showed three peaks that could not be assigned to a means of our HPLC-UV-Vis Database (Figure 3).

Fermentation and Isolation
Batch fermentations of strain AB-18-032 were carried out in complex medium and yielded 60 mg/L of abyssomicin C and atrop time of 96 h. The fermentation broth was separated by multiple she filtrate and mycelium. Abyssomicins were isolated from the cultu XAD-16 chromatography, desorbed with a step gradient H2O-MeO concentration with ethyl acetate at pH 5. Abyssomicins were puri umn chromatography on Sephadex LH-20 using MeOH as eluent, CH2Cl2-MeOH gradient elution [2]. Pure abyssomicin C and atro obtained by preparative reversed-phase HPLC on Nucleosil-C18 ent elution, and lyophilization of the separated eluates.

Structure Elucidation and Synthesis Strategies
From abyssomicin B, C, and D, single crystals were obtained figuration was determined by X-ray structure. NMR analyses co

Fermentation and Isolation
Batch fermentations of strain AB-18-032 were carried out in the 10-litre scale in a complex medium and yielded 60 mg/L of abyssomicin C and atrop-C after a fermentation time of 96 h. The fermentation broth was separated by multiple sheet filtration into culture filtrate and mycelium. Abyssomicins were isolated from the culture filtrate by Amberlite XAD-16 chromatography, desorbed with a step gradient H 2 O-MeOH, and extracted after concentration with ethyl acetate at pH 5. Abyssomicins were purified by subsequent column chromatography on Sephadex LH-20 using MeOH as eluent, and on silica-diol with CH 2 Cl 2 -MeOH gradient elution [2]. Pure abyssomicin C and atrop-C, respectively, were obtained by preparative reversed-phase HPLC on Nucleosil-C18 and H 2 O-MeOH gradient elution, and lyophilization of the separated eluates.

Structure Elucidation and Synthesis Strategies
From abyssomicin B, C, and D, single crystals were obtained, and their relative configuration was determined by X-ray structure. NMR analyses confirmed the X-ray data [3]. The absolute stereochemistry was determined by both the Mosher method [11] and the Helmchen method [12].
A detailed analysis of the culture filtrate from fermentations of strain AB-18-032 revealed two additional signals in the chromatogram of HPLC-DAD-ESI-MS runs that were related to abyssomicins according to their UV-visible properties, and besides abyssomicin C, the presence of atrop-abyssomicin C as the main product of strain AB-18-032 could be confirmed [4]. The compounds, abyssomicin G and H, were isolated from the culture filtrate of the fermentation of strain AB-18-032 in analogy to abyssomicins B-D, and the purified  Abyssomicin C was the topic of several total synthetic strategies, based o and complex spirotetronate structure, and on the need for structure optim regard to clinical applications. The group of Erik J. Sorensen published a Diels rocyclization that enabled an efficient asymmetric synthesis of abyssomicin group of Martin E. Maier prepared the synthesis of the core structure of ab containing an oxybicyclooctane ring and a tetronate by a Diels-Alder strateg ther strategy for the synthesis of abyssomicins C and D was reported by the gr B. Snider [15]. While working on another route for the total synthesis of aby the group of Kyriacos C. Nicolaou discovered atrop-abyssomicin C, a nov abyssomicin C [16]. Atrop-abyssomicin C was found simultaneously as a nat of Verrucosispora maris AB-18-032 [4]. The importance of spirotetronate an their improved synthetic routes are highlighted in two review articles by the g Theodorakis [17,18].
Continuous interest in abyssomicins has been shown by Vidali et al., a mimetic approaches toward the synthesis of abyssomicin C and atrop-ab based on an intramolecular Diels-Alder reaction of a butenolide derivative a keto-triene side chain [19].

Biological Activity and Mode of Action
Among all abyssomicins, only abyssomicin C and atrop-abyssomicin strong antimicrobial activity, which is restricted to Gram-positive bacteria. Th of atrop-abyssomicin C against multi-resistant Staphylococcus aureus N313 wa MIC values in the range of 13-16 µg/mL were determined against vancomy S. aureus Mu50, Enterococcus faecalis VanA, VanB, and E. faecium VanA, and a resistant S. epidermidis CNS 184. Abyssomicin C showed 1.5-fold lowered compared to atrop-abyssomicin C. Gram-negative bacteria, filamentous fung Abyssomicin C was the topic of several total synthetic strategies, based on its unique and complex spirotetronate structure, and on the need for structure optimization with regard to clinical applications. The group of Erik J. Sorensen published a Diels-Alder macrocyclization that enabled an efficient asymmetric synthesis of abyssomicin C [13]. The group of Martin E. Maier prepared the synthesis of the core structure of abyssomicin C containing an oxybicyclooctane ring and a tetronate by a Diels-Alder strategy [14]. A further strategy for the synthesis of abyssomicins C and D was reported by the group of Barry B. Snider [15]. While working on another route for the total synthesis of abyssomicin C, the group of Kyriacos C. Nicolaou discovered atrop-abyssomicin C, a novel isomer of abyssomicin C [16]. Atrop-abyssomicin C was found simultaneously as a natural product of Verrucosispora maris AB-18-032 [4]. The importance of spirotetronate antibiotics and their improved synthetic routes are highlighted in two review articles by the group of E.A. Theodorakis [17,18].
Continuous interest in abyssomicins has been shown by Vidali et al., applying biomimetic approaches toward the synthesis of abyssomicin C and atrop-abyssomicin C based on an intramolecular Diels-Alder reaction of a butenolide derivative attached to a keto-triene side chain [19].

Biological Activity and Mode of Action
Among all abyssomicins, only abyssomicin C and atrop-abyssomicin C showed a strong antimicrobial activity, which is restricted to Gram-positive bacteria. The MIC value of atrop-abyssomicin C against multi-resistant Staphylococcus aureus N313 was 3.5 µg/mL. MIC values in the range of 13-16 µg/mL were determined against vancomycin-resistant S. aureus Mu50, Enterococcus faecalis VanA, VanB, and E. faecium VanA, and against multiresistant S. epidermidis CNS 184. Abyssomicin C showed 1.5-fold lowered MIC values compared to atrop-abyssomicin C. Gram-negative bacteria, filamentous fungi, and yeasts were not sensitive against abyssomicin C and atrop-abyssomicin C [2,4].
Abyssomicin C and atrop-abyssomicin C were the first known natural inhibitors of pAba biosynthesis. Two enzymes catalyze pAba biosynthesis from chorismate, 4-amino-4deoxychorismate (ADC) synthase, which converts chorismate and glutamine into ADC and glutamate, and ADC lyase, which catalyzes an elimination reaction of ADC to produce pAba. ADC synthase is a heterodimer composed of two nonidentical subunits, PabA and PabB. PabA functions as a glutamine amidotransferase, while PabB catalyzes the substitution of the chorismate 4-hydroxy group by an amino group while retaining the original configuration. The Süssmuth group has shown that the PabB subunit of ADC synthase is the molecular target of abyssomicin C and atrop-abyssomicin C. The antibiotics act as covalent binders in a Michael addition to the side chain of Cys 263, located in the proximity of the active site of PabB, and inhibit pAba formation and, consequently, folate biosynthesis [5]. The increased antimicrobial activity of atrop-abyssomicin C can be explained by its more powerful Michael acceptor properties [16].
The oxabicyclooctane ring system of abyssomicin C, and atrop-abyssomicin B shows a striking similarity to one solution conformation of chorismate, which suggests that both antibiotics act as substrate mimetics ( Figure 5).
Drugs 2021, 19, x FOR PEER REVIEW Abyssomicin C and atrop-abyssomicin C were the first known pAba biosynthesis. Two enzymes catalyze pAba biosynthesis from 4-deoxychorismate (ADC) synthase, which converts chorismate and and glutamate, and ADC lyase, which catalyzes an elimination rea duce pAba. ADC synthase is a heterodimer composed of two nonide and PabB. PabA functions as a glutamine amidotransferase, while Pa stitution of the chorismate 4-hydroxy group by an amino group whi nal configuration. The Süssmuth group has shown that the PabB sub is the molecular target of abyssomicin C and atrop-abyssomicin C. covalent binders in a Michael addition to the side chain of Cys 263, l ity of the active site of PabB, and inhibit pAba formation and, conseq thesis [5]. The increased antimicrobial activity of atrop-abyssomici by its more powerful Michael acceptor properties [16].
The oxabicyclooctane ring system of abyssomicin C, and atropa striking similarity to one solution conformation of chorismate, wh antibiotics act as substrate mimetics ( Figure 5).

Taxonomy of the Producing Strain
Strain AB-18-032 was isolated from a sediment collected from depth of 289 meters in August 1991 as an outcome of the collabor (University of Kent) and Koki Horikoshi (JAMSTEC Tokyo). The s the family Micromonosporaceae based on its morphological and chem ties [2]. A scanning electron micrograph is shown in Figure 6.

Taxonomy of the Producing Strain
Strain AB-18-032 was isolated from a sediment collected from the Sea of Japan at a depth of 289 meters in August 1991 as an outcome of the collaboration of Alan T. Bull (University of Kent) and Koki Horikoshi (JAMSTEC Tokyo). The strain was assigned to the family Micromonosporaceae based on its morphological and chemotaxonomic properties [2]. A scanning electron micrograph is shown in Figure 6.
The comparison of the nearly complete 16S rDNA gene sequence of strain AB-18-032, with corresponding sequences of representatives of the suborder Micromonosporineae showed that strain AB-18-032 is closely related to Verrucosispora gifhornensis, the sole representative of the genus Verrucosispora at this time (Figure 7).
The complete characterization of Verrucosispora sp. AB-18-032 was done by polyphasic taxonomy by the group of Michael Goodfellow (Newcastle University) [6]. Apparent from the combined phenotypic and genotypic data, the strain was classified in the genus Verrucosispora as a new species and described as Verrucosispora maris sp. nov. (=DSM 45365 T = NRRLB-24793 T ). depth of 289 meters in August 1991 as an outcome of th (University of Kent) and Koki Horikoshi (JAMSTEC Toky the family Micromonosporaceae based on its morphological ties [2]. A scanning electron micrograph is shown in Figur   Figure 6. Scanning electron micrograph of Verrucosispora sp. ABpermission from [2], copyright owned by Japan Antibiotics Resea The comparison of the nearly complete 16S rDNA gen with corresponding sequences of representatives of the showed that strain AB-18-032 is closely related to Verrucos resentative of the genus Verrucosispora at this time (Figure The complete characterization of Verrucosispora sp. AB-18-032 wa phasic taxonomy by the group of Michael Goodfellow (Newcastle Unive ent from the combined phenotypic and genotypic data, the strain was genus Verrucosispora as a new species and described as Verrucosispora

Increased Abyssomicin Spectrum
Several new members of the abyssomicin family were published during the last years. Abyssomicin E was isolated 2007 from terrestric Streptomyces sp. HKI0381. Abyssomicin E is similar in structure to abyssomicin D, and showed no biological activity [20]. In 2010, the structure of abyssomicin I produced by soil-derived Streptomyces sp. CHI39 was published. The compound exhibited inhibitory effects on tumor cell invasion [21]. One year later, the structures of ent-homoabyssomicins A and B were published, isolated from forest soil Streptomyces sp. Ank 210 [22]. Abyssomicins J, K, and L were isolated in 2013 from the South China Sea deep-sea sediment Verrucosispora sp. MS100128, showing anti-tuberculosis effects [23]. Abyssomicins 2-5 were produced by the marine-derived Streptomyces sp. RLUS1487 and were published in 2015. Abyssomicin 2 was identified as a selective reactivator of latent HIV virus [24]. In 2017, neoabyssomicins A-C were published, isolated from the deep-sea-derived Streptomyces koyangensis SCSIO. Neoabyssomicin A was found to augment HIV-1 virus replication in a human lymphocyte model [25]. In the same year, abyssomicins M-X were isolated from the coalmine fire strain Streptomyces sp. LC-6-2. The compounds were inactive in standard antimicrobial and cancer cell line cytotoxicity assays [26]. Abyssomicin Y was published in 2020 and is, to the best of my knowledge, the newest member of the abyssomicin family; it is produced by the marine-derived strain Verrucosispora sp. MS100137. The compound exhibited anti-influenza A virus activity [27].
The structures of the new members of the abyssomicin family are summarized in a review article by Sadaka et al. [9].
Funding: This research received no external funding.